This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Hydroxyprogesterone
Accession Number
DB14570
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
  • 17-Hydroxypregn-4-en-3,20-dione
  • 17-hydroxyprogesterone
  • 17alpha-hydroxyprogesterone
  • 17α-hydroxyprogesterone
  • delta(4)-Pregnene-17alpha-ol-3,20-dione
  • Hidroxiprogesterona
  • Hydroxyprogesterone
  • Hydroxyprogesteronum
  • Pregn-4-ene-3,20-dione-17-ol
Categories
UNII
21807M87J2
CAS number
68-96-2
Weight
Average: 330.4611
Monoisotopic: 330.219494826
Chemical Formula
C21H30O3
InChI Key
DBPWSSGDRRHUNT-CEGNMAFCSA-N
InChI
InChI=1S/C21H30O3/c1-13(22)21(24)11-8-18-16-5-4-14-12-15(23)6-9-19(14,2)17(16)7-10-20(18,21)3/h12,16-18,24H,4-11H2,1-3H3/t16-,17+,18+,19+,20+,21+/m1/s1
IUPAC Name
(1R,3aS,3bR,9aR,9bS,11aS)-1-acetyl-1-hydroxy-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one
SMILES
[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinHydroxyprogesterone may decrease the anticoagulant activities of (R)-warfarin.
(S)-WarfarinHydroxyprogesterone may decrease the anticoagulant activities of (S)-Warfarin.
AbciximabHydroxyprogesterone may decrease the anticoagulant activities of Abciximab.
Acetylsalicylic acidHydroxyprogesterone may decrease the anticoagulant activities of Acetylsalicylic acid.
AlteplaseHydroxyprogesterone may decrease the anticoagulant activities of Alteplase.
AmediplaseHydroxyprogesterone may decrease the anticoagulant activities of Amediplase.
AnagrelideHydroxyprogesterone may decrease the anticoagulant activities of Anagrelide.
AncrodHydroxyprogesterone may decrease the anticoagulant activities of Ancrod.
AnistreplaseHydroxyprogesterone may decrease the anticoagulant activities of Anistreplase.
Antithrombin AlfaHydroxyprogesterone may decrease the anticoagulant activities of Antithrombin Alfa.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0000374
KEGG Compound
C01176
ChemSpider
6002
BindingDB
50423511
ChEBI
17252
ChEMBL
CHEMBL1062
HET
3QZ
Wikipedia
17%CE%B1-Hydroxyprogesterone
ATC Codes
G03FA02 — Hydroxyprogesterone and estrogenG03DA03 — Hydroxyprogesterone
PDB Entries
3qz1 / 4nky / 5ier / 5if6 / 5vbu

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2CompletedTreatmentComplications, Pregnancy1
2, 3RecruitingTreatmentPremature Births1
3Active Not RecruitingPreventionAbsorption; Chemicals / Premature Births1
4Not Yet RecruitingTreatmentPreeclampsia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0293 mg/mLALOGPS
logP2.99ALOGPS
logP3.4ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)12.7ChemAxon
pKa (Strongest Basic)-3.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.37 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity94.11 m3·mol-1ChemAxon
Polarizability37.9 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (2 MEOX; 1 TMS)GC-MSsplash10-004l-4911000000-d40ba45835d1ee1b6c41
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-002o-9651000000-b44110f9abcffa42ce35
GC-MS Spectrum - GC-MSGC-MSsplash10-004l-4911000000-d40ba45835d1ee1b6c41
Mass Spectrum (Electron Ionization)MSsplash10-002f-9731000000-48d2266d41955ffa9ce4
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-001i-0009000000-a157e4b4aa18bdbc2531
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-052b-5900000000-42494c0ef4b45cfa5cf4
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-052b-9700000000-d8a942a3dfdb061bd5c3
MS/MS Spectrum - EI-B (HITACHI M-80) , PositiveLC-MS/MSsplash10-002o-9651000000-b0c55e50343bf8ab3077
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4j-4930000000-c5056c0aac78a148ea92
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
20-oxosteroids / 3-oxo delta-4-steroids / 17-hydroxysteroids / Delta-4-steroids / Cyclohexenones / Tertiary alcohols / Alpha-hydroxy ketones / Cyclic alcohols and derivatives / Organic oxides / Hydrocarbon derivatives
Substituents
Progestogin-skeleton / 20-oxosteroid / 3-oxo-delta-4-steroid / 3-oxosteroid / 17-hydroxysteroid / Oxosteroid / Hydroxysteroid / Delta-4-steroid / Cyclohexenone / Alpha-hydroxy ketone
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
17alpha-hydroxy steroid (CHEBI:17252) / Progestagens (C01176) / C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030161)

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Bustos ML, Caritis SN, Jablonski KA, Reddy UM, Sorokin Y, Manuck T, Varner MW, Wapner RJ, Iams JD, Carpenter MW, Peaceman AM, Mercer BM, Sciscione A, Rouse DJ, Ramin SM: The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth. Am J Obstet Gynecol. 2017 Sep;217(3):369.e1-369.e9. doi: 10.1016/j.ajog.2017.05.019. Epub 2017 May 15. [PubMed:28522317]

Drug created on July 20, 2018 15:05 / Updated on December 02, 2019 10:14